Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Simon J.A. et al.

The 52-week open-label extension to RECONNECT. Tolerability stays bumpy — nausea, flushing, transient blood-pressure rises — but the women who continued kept the desire and distress gains. The longest-duration PT-141 dataset that exists in humans.

Comninos A.N. et al.

Resting-state fMRI follow-up: kisspeptin alters default-mode connectivity in ways that track with self-reported sexual and emotional improvements. Same lab, same population — and the most provocative paper for the idea that kisspeptin might one day target HSDD upstream of bremelanotide.

Comninos A.N. et al.

The Dhillo group's fMRI work showing IV kisspeptin shifts limbic activity in heterosexual men during sexual and emotional image processing. Mechanism, not therapy — but the cleanest human evidence that kisspeptin acts above the hypothalamus, not just within it.

Dhillo W.S. et al.

The first-in-human kisspeptin paper. IV kisspeptin-54 raised LH, FSH, and testosterone in healthy men — proving the rodent biology translates. Everything written since about kisspeptin as a fertility and reproductive-endocrinology tool starts here.